Tuberculosis vaccines: present and future

References

• Global Tuberculosis Control – Surveillance, Planning, Financing. WHO Report (2008).
   Google Scholar
• Matteelli A, Migliori GB, Cirillo D, Centis R, Girard E, Raviglion M. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev. Anti. Infect. Ther.5(5), 857–871 (2007).
   PubMed Web of Science ®Google Scholar
• Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA293(22), 2767–2775 (2005).
   PubMed Web of Science ®Google Scholar
• Corbett EL, Watt CJ, Walker N et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med.163(9), 1009–1021 (2003).
   PubMed Web of Science ®Google Scholar
• Girardi E, Raviglione MC, Antonucci G, Godfrey-Faussett P, Ippolito G. Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. AIDS14(Suppl. 3), S47–S56 (2000).
   PubMed Web of Science ®Google Scholar
• Stop TB Partnership. The global plan to stop TB, 2006–2015. Actions for life: towards a world free of tuberculosis. Int. J. Tuberc. Lung Dis.10(3), 240–241 (2006).
   Google Scholar
• Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost–effectiveness. Lancet367(9517), 1173–1180 (2006).
   PubMed Web of Science ®Google Scholar
• Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA271(9), 698–702 (1994).
   PubMed Web of Science ®Google Scholar
• Ritz N, Hanekom WA, Robins-Browne R, Britton WJ, Curtis N. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol. Rev.32(5), 821–841 (2008).
   PubMed Web of Science ®Google Scholar
• Brandt L, Feino Cunha J, Weinreich Olsen A et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun.70(2), 672–678 (2002).
   PubMed Web of Science ®Google Scholar
• Black GF, Dockrell HM, Crampin AC et al. Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in Northern Malawi. J. Infect. Dis.184(3), 322–329 (2001).
   PubMed Web of Science ®Google Scholar
• Palmer CE, Long MW. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am. Rev. Respir. Dis.94(4), 553–568 (1966).
   PubMed Web of Science ®Google Scholar
• Weir RE, Black GF, Nazareth B et al. The influence of previous exposure to environmental mycobacteria on the interferon-γ response to bacille Calmette–Guerin vaccination in Southern England and Northern Malawi. Clin. Exp. Immunol.146(3), 390–399 (2006).
   PubMed Web of Science ®Google Scholar
• Elias D, Britton S, Aseffa A, Engers H, Akuffo H. Poor immunogenicity of BCG in helminth infected population is associated with increased in vitro TGF-β production. Vaccine26(31), 3897–3902 (2008).
   PubMed Web of Science ®Google Scholar
• Behr MA, Wilson MA, Gill WP et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science284(5419), 1520–1523 (1999).
   PubMed Web of Science ®Google Scholar
• Brosch R, Gordon SV, Garnier T et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc. Natl Acad. Sci. USA104(13), 5596–5601 (2007).
   PubMed Web of Science ®Google Scholar
• Davids V, Hanekom WA, Mansoor N et al. The effect of bacille Calmette–Guerin vaccine strain and route of administration on induced immune responses in vaccinated infants. J. Infect. Dis.193(4), 531–536 (2006).
   PubMed Web of Science ®Google Scholar
• Hesseling AC, Rabie H, Marais BJ et al. Bacille Calmette–Guerin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin. Infect. Dis.42(4), 548–558 (2006).
   PubMed Web of Science ®Google Scholar
• Knezevic I, Corbel MJ. WHO discussion on the improvement of the quality control of BCG vaccines. Vaccine24(18), 3874–3877 (2006).
   Google Scholar
• Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. A framework for assessing immunological correlates of protection in vaccine trials. J. Infect. Dis.196(9), 1304–1312 (2007).
   PubMed Web of Science ®Google Scholar
• Beveridge NE, Fletcher HA, Hughes J et al. A comparison of IFNγ detection methods used in tuberculosis vaccine trials. 88(6), 631–640 (2008).
   Google Scholar
• Ladel CH, Daugelat S, Kaufmann SH. Immune response to Mycobacterium bovis bacille Calmette–Guerin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Eur. J. Immunol.25(2), 377–384 (1995).
   PubMed Web of Science ®Google Scholar
• Caruso AM, Serbina N, Klein E, Triebold K, Bloom BR, Flynn JL. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-γ, yet succumb to tuberculosis. J. Immunol.162(9), 5407–5416 (1999).
   PubMed Web of Science ®Google Scholar
• Saunders BM, Frank AA, Orme IM, Cooper AM. CD4 is required for the development of a protective granulomatous response to pulmonary tuberculosis. Cell. Immunol.216(1–2), 65–72 (2002).
   PubMed Web of Science ®Google Scholar
• Scanga CA, Mohan VP, Yu K et al. Depletion of CD4(+) T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon gamma and nitric oxide synthase 2. J. Exp. Med.192(3), 347–358 (2000).
   PubMed Web of Science ®Google Scholar
• Cowley SC, Elkins KL. CD4+ T cells mediate IFN-γ-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo. J. Immunol.171(9), 4689–4699 (2003).
   PubMed Web of Science ®Google Scholar
• Feng CG, Britton WJ. CD4+ and CD8+ T cells mediate adoptive immunity to aerosol infection of Mycobacterium bovis bacillus Calmette–Guerin. J. Infect. Dis.181(5), 1846–1849 (2000).
   PubMed Web of Science ®Google Scholar
• Wangoo A, Sparer T, Brown IN et al. Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J. Immunol.166(5), 3432–3439 (2001).
   PubMed Web of Science ®Google Scholar
• Andersen P, Smedegaard B. CD4(+) T-cell subsets that mediate immunological memory to Mycobacterium tuberculosis infection in mice. Infect. Immun.68(2), 621–629 (2000).
   PubMedGoogle Scholar
• Aaron L, Saadoun D, Calatroni I et al. Tuberculosis in HIV-infected patients: a comprehensive review. Clin. Microbiol. Infect.10(5), 388–398 (2004).
   PubMed Web of Science ®Google Scholar
• Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am. Rev. Respir. Dis.148(5), 1292–1297 (1993).
   PubMed Web of Science ®Google Scholar
• Steinman L. A brief history of T(h)17, the first major revision in the T(h)1/T(h)2 hypothesis of T cell-mediated tissue damage. Nat. Med.13(2), 139–145 (2007).
   PubMed Web of Science ®Google Scholar
• Wozniak TM, Ryan AA, Britton WJ. Interleukin-23 restores immunity to Mycobacterium tuberculosis infection in IL-12p40-deficient mice and is not required for the development of IL-17-secreting T cell responses. J. Immunol.177(12), 8684–8692 (2006).
   PubMed Web of Science ®Google Scholar
• Khader SA, Bell GK, Pearl JE et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol.8(4), 369–377 (2007).
   PubMed Web of Science ®Google Scholar
• Khader SA, Cooper AM. IL-23 and IL-17 in tuberculosis. Cytokine41(2), 79–83 (2008).
   PubMed Web of Science ®Google Scholar
• Lockhart E, Green AM, Flynn JL. IL-17 production is dominated by γδ T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J. Immunol.177(7), 4662–4669 (2006).
   PubMed Web of Science ®Google Scholar
• Umemura M, Yahagi A, Hamada S et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette–Guerin infection. J. Immunol.178(6), 3786–3796 (2007).
   PubMed Web of Science ®Google Scholar
• Peng MY, Wang ZH, Yao CY et al. Interleukin 17-producing γ δ T cells increased in patients with active pulmonary tuberculosis. Cell. Mol. Immunol.5(3), 203–208 (2008).
   PubMed Web of Science ®Google Scholar
• Happel KI, Lockhart EA, Mason CM et al. Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs. Infect. Immun.73(9), 5782–5788 (2005).
   PubMed Web of Science ®Google Scholar
• Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon γ gene-disrupted mice. J. Exp. Med.178(6), 2243–2247 (1993).
   PubMed Web of Science ®Google Scholar
• Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl Acad. Sci. USA89(24), 12013–12017 (1992).
   PubMed Web of Science ®Google Scholar
• Derrick SC, Repique C, Snoy P, Yang AL, Morris S. Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis. Infect. Immun.72(3), 1685–1692 (2004).
   PubMed Web of Science ®Google Scholar
• van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur. J. Immunol.30(12), 3689–3698 (2000).
   PubMed Web of Science ®Google Scholar
• Stenger S, Hanson DA, Teitelbaum R et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science282(5386), 121–125 (1998).
   PubMed Web of Science ®Google Scholar
• Boom WH. New TB vaccines: is there a requirement for CD8 T cells? J. Clin. Invest.117(8), 2092–2094 (2007).
   PubMedGoogle Scholar
• Hinchey J, Lee S, Jeon BY et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J. Clin. Invest.117(8), 2279–2288 (2007).
   PubMed Web of Science ®Google Scholar
• Hoft DF. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet372(9633), 164–175 (2008).
   PubMed Web of Science ®Google Scholar
• Flynn JL, Chan J. Immunology of tuberculosis. Annu. Rev. Immunol.19, 93–129 (2001).
   PubMed Web of Science ®Google Scholar
• Lewinsohn DM, Lewinsohn DA, Grotzke JE. TB vaccines at the turn of the century: insights into immunity to M. tuberculosis and modern approaches for prevention of an ancient disease. Semin. Respir. Infect.18(4), 320–338 (2003).
   Google Scholar
• Mehra V, Gong JH, Iyer D et al. Immune response to recombinant mycobacterial proteins in patients with tuberculosis infection and disease. J. Infect. Dis.174(2), 431–434 (1996).
   Google Scholar
• Sanchez FO, Rodriguez JI, Agudelo G, Garcia LF. Immune responsiveness and lymphokine production in patients with tuberculosis and healthy controls. Infect. Immun.62(12), 5673–5678 (1994).
   PubMed Web of Science ®Google Scholar
• Newport MJ, Huxley CM, Huston S et al. A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med.335(26), 1941–1949 (1996).
   PubMed Web of Science ®Google Scholar
• Dorman SE, Picard C, Lammas D et al. Clinical features of dominant and recessive interferon γ receptor 1 deficiencies. Lancet364(9451), 2113–2121 (2004).
   PubMed Web of Science ®Google Scholar
• Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon γ in resistance to Mycobacterium tuberculosis infection. J. Exp. Med.178(6), 2249–2254 (1993).
   PubMed Web of Science ®Google Scholar
• Jouanguy E, Altare F, Lamhamedi S et al. Interferon-γ-receptor deficiency in an infant with fatal bacille Calmette–Guerin infection. N. Engl. J. Med.335(26), 1956–1961 (1996).
   PubMed Web of Science ®Google Scholar
• Bonecini-Almeida MG, Chitale S, Boutsikakis I et al. Induction of in vitro human macrophage anti-Mycobacterium tuberculosis activity: requirement for IFN-γ and primed lymphocytes. J. Immunol.160(9), 4490–4499 (1998).
   Google Scholar
• Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol. Lancet349(9064), 1513–1515 (1997).
   PubMed Web of Science ®Google Scholar
• Silver RF, Li Q, Boom WH, Ellner JJ. Lymphocyte-dependent inhibition of growth of virulent Mycobacterium tuberculosis H37Rv within human monocytes: requirement for CD4+ T cells in purified protein derivative-positive, but not in purified protein derivative-negative subjects. J. Immunol.160(5), 2408–2417 (1998).
   PubMed Web of Science ®Google Scholar
• Hope JC, Thom ML, Villarreal-Ramos B, Vordermeier HM, Hewinson RG, Howard CJ. Vaccination of neonatal calves with Mycobacterium bovis BCG induces protection against intranasal challenge with virulent M. bovis. Clin. Exp. Immunol.139(1), 48–56 (2005).
   PubMedGoogle Scholar
• Buddle BM, Denis M, Aldwell FE, Martin Vordermeier H, Glyn Hewinson R, Neil Wedlock D. Vaccination of cattle with Mycobacterium bovis BCG by a combination of systemic and oral routes. Tuberculosis (Edinb.)88(6), 595–600 (2008).
   PubMedGoogle Scholar
• Soares AP, Scriba TJ, Joseph S et al. Bacillus Calmette–Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J. Immunol.180(5), 3569–3577 (2008).
   PubMed Web of Science ®Google Scholar
• Gardam MA, Keystone EC, Menzies R et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect. Dis.3(3), 148–155 (2003).
   PubMed Web of Science ®Google Scholar
• Jacobs M, Togbe D, Fremond C et al. Tumor necrosis factor is critical to control tuberculosis infection. Microbes Infect.9(5), 623–628 (2007).
   PubMed Web of Science ®Google Scholar
• Allie N, Alexopoulou L, Quesniaux VJ et al. Protective role of membrane tumour necrosis factor in the host’s resistance to mycobacterial infection. Immunology125(4), 522–534 (2008).
   Google Scholar
• Campbell JJ, Murphy KE, Kunkel EJ et al. CCR7 expression and memory T cell diversity in humans. J. Immunol.166(2), 877–884 (2001).
   PubMed Web of Science ®Google Scholar
• Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4+ T cells. J. Exp. Med.194(12), 1711–1719 (2001).
   PubMed Web of Science ®Google Scholar
• Chambers MA, Marshall BG, Wangoo A et al. Differential responses to challenge with live and dead Mycobacterium bovis Bacillus Calmette–Guerin. J. Immunol.158(4), 1742–1748 (1997).
   PubMedGoogle Scholar
• Whelan AO, Wright DC, Chambers MA, Singh M, Hewinson RG, Vordermeier HM. Evidence for enhanced central memory priming by live Mycobacterium bovis BCG vaccine in comparison with killed BCG formulations. Vaccine26(2), 166–173 (2008).
   Google Scholar
• Buentke E, Mathiot A, Tolaini M, Di Santo J, Zamoyska R, Seddon B. Do CD8 effector cells need IL-7R expression to become resting memory cells? Blood108(6), 1949–1956 (2006).
   Google Scholar
• Onoda T, Rahman M, Nara H et al. Human CD4+ central and effector memory T cells produce IL-21: effect on cytokine-driven proliferation of CD4+ T cell subsets. Int. Immunol.19(10), 1191–1199 (2007).
   PubMed Web of Science ®Google Scholar
• Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat. Rev. Immunol.3(4), 269–279 (2003).
   PubMed Web of Science ®Google Scholar
• Ribeiro-Rodrigues R, Resende Co T, Rojas R et al. A role for CD4+CD25+ T cells in regulation of the immune response during human tuberculosis. Clin. Exp. Immunol.144(1), 25–34 (2006).
   PubMed Web of Science ®Google Scholar
• Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am. J. Respir. Crit. Care Med.173(7), 803–810 (2006).
   PubMedGoogle Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science299(5609), 1057–1061 (2003).
   PubMed Web of Science ®Google Scholar
• Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol.4(4), 337–342 (2003).
   PubMed Web of Science ®Google Scholar
• Leng Q, Bentwich Z, Borkow G. Increased TGF-β, Cbl-b and CTLA-4 levels and immunosuppression in association with chronic immune activation. Int. Immunol.18(5), 637–644 (2006).
   PubMed Web of Science ®Google Scholar
• Mahanty S, Mollis SN, Ravichandran M et al. High levels of spontaneous and parasite antigen-driven interleukin-10 production are associated with antigen-specific hyporesponsiveness in human lymphatic filariasis. J. Infect. Dis.173(3), 769–773 (1996).
   Google Scholar
• Doetze A, Satoguina J, Burchard G et al. Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is mediated by T(h)3/T(r)1-type cytokines IL-10 and transforming growth factor-β but not by a T(h)1 to T(h)2 shift. Int. Immunol.12(5), 623–630 (2000).
   PubMed Web of Science ®Google Scholar
• Huygen K, Content J, Denis O et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat. Med.2(8), 893–898 (1996).
   PubMed Web of Science ®Google Scholar
• Skjot RL, Oettinger T, Rosenkrands I et al. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect. Immun.68(1), 214–220 (2000).
   PubMed Web of Science ®Google Scholar
• Dillon DC, Alderson MR, Day CH et al. Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect. Immun.67(6), 2941–2950 (1999).
   PubMed Web of Science ®Google Scholar
• Alderson MR, Bement T, Day CH et al. Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells. J. Exp. Med.191(3), 551–560 (2000).
   PubMedGoogle Scholar
• Skeiky YA, Ovendale PJ, Jen S et al. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J. Immunol.165(12), 7140–7149 (2000).
   PubMed Web of Science ®Google Scholar
• Bastian M, Braun T, Bruns H, Rollinghoff M, Stenger S. Mycobacterial lipopeptides elicit CD4+ CTLs in Mycobacterium tuberculosis-infected humans. J. Immunol.180(5), 3436–3446 (2008).
   PubMed Web of Science ®Google Scholar
• Lin MY, Ottenhoff TH. Not to wake a sleeping giant: new insights into host–pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection. Biol. Chem.389(5), 497–511 (2008).
   PubMed Web of Science ®Google Scholar
• Locht C, Hougardy JM, Rouanet C, Place S, Mascart F. Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. Tuberculosis (Edinb.)86(3–4), 303–309 (2006).
   PubMed Web of Science ®Google Scholar
• Hougardy JM, Schepers K, Place S et al. Heparin-binding-hemagglutinin-induced IFN-γ release as a diagnostic tool for latent tuberculosis. PLoS ONE2(10), E926 (2007).
   PubMed Web of Science ®Google Scholar
• TB Vaccines for the World 2008 Conference, Atlanta, GA, USA, 9–11 April 2008.
   Google Scholar
• Lewin A, Baus D, Kamal E et al. The mycobacterial DNA-binding protein 1 (MDP1) from Mycobacterium bovis BCG influences various growth characteristics. BMC Microbiol.8, 91 (2008).
   Google Scholar
• Kana BD, Gordhan BG, Downing KJ et al. The resuscitation-promoting factors of Mycobacterium tuberculosis are required for virulence and resuscitation from dormancy but are collectively dispensable for growth in vitro. Mol. Microbiol.67(3), 672–684 (2008).
   PubMed Web of Science ®Google Scholar
• Russell-Goldman E, Xu J, Wang X, Chan J, Tufariello JM. A Mycobacterium tuberculosis Rpf double-knockout strain exhibits profound defects in reactivation from chronic tuberculosis and innate immunity phenotypes. Infect. Immun.76(9), 4269–4281 (2008).
   PubMed Web of Science ®Google Scholar
• Lin MY, Geluk A, Smith SG et al. Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination. Infect. Immun.75(7), 3523–3530 (2007).
   PubMed Web of Science ®Google Scholar
• Andersen P. Vaccine strategies against latent tuberculosis infection. Trends Microbiol.15(1), 7–13 (2007).
   PubMed Web of Science ®Google Scholar
• Rustad TR, Harrell MI, Liao R, Sherman DR. The enduring hypoxic response of Mycobacterium tuberculosis. PLoS ONE3(1), E1502 (2008).
   PubMed Web of Science ®Google Scholar
• Weir RE, Gorak-Stolinska P, Floyd S et al. Persistence of the immune response induced by BCG vaccination. BMC Infect. Dis.8, 9 (2008).
   PubMedGoogle Scholar
• Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette–Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol.171(3), 1602–1609 (2003).
   PubMed Web of Science ®Google Scholar
• McShane H, Pathan AA, Sander CR et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med.10(11), 1240–1244 (2004).
   PubMed Web of Science ®Google Scholar
• Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet348(9019), 17–24 (1996).
   PubMed Web of Science ®Google Scholar
• Rodrigues LC, Pereira SM, Cunha SS et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet366(9493), 1290–1295 (2005).
   PubMed Web of Science ®Google Scholar
• Brandt L, Skeiky YA, Alderson MR et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun.72(11), 6622–6632 (2004).
   PubMed Web of Science ®Google Scholar
• Skeiky YA, Alderson MR, Ovendale PJ et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol.172(12), 7618–7628 (2004).
   PubMed Web of Science ®Google Scholar
• Tsenova L, Harbacheuski R, Moreira AL et al. Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect. Immun.74(4), 2392–2401 (2006).
   PubMed Web of Science ®Google Scholar
• Langermans JA, Doherty TM, Vervenne RA et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine23(21), 2740–2750 (2005).
   PubMed Web of Science ®Google Scholar
• Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect. Immun.72(10), 6148–6150 (2004).
   PubMed Web of Science ®Google Scholar
• Dietrich J, Aagaard C, Leah R et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J. Immunol.174(10), 6332–6339 (2005).
   PubMed Web of Science ®Google Scholar
• Agger EM, Rosenkrands I, Olsen AW et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine24(26), 5452–5460 (2006).
   PubMed Web of Science ®Google Scholar
• Christensen D, Foged C, Rosenkrands I, Nielsen HM, Andersen P, Agger EM. Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying. Biochim. Biophys. Acta1768(9), 2120–2129 (2007).
   PubMed Web of Science ®Google Scholar
• Williams A, Goonetilleke NP, McShane H et al. Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect. Immun.73(6), 3814–3816 (2005).
   PubMed Web of Science ®Google Scholar
• Radosevic K, Wieland CW, Rodriguez A et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of γ interferon. Infect. Immun.75(8), 4105–4115 (2007).
   PubMed Web of Science ®Google Scholar
• Sambandamurthy VK, Wang X, Chen B et al. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat. Med.8(10), 1171–1174 (2002).
   PubMed Web of Science ®Google Scholar
• Sambandamurthy VK, Derrick SC, Jalapathy KV et al. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect. Immun.73(2), 1196–1203 (2005).
   PubMed Web of Science ®Google Scholar
• Sambandamurthy VK, Derrick SC, Hsu T et al.Mycobacterium tuberculosis DRD1 ΔpanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine24(37–39), 6309–6320 (2006).
   PubMed Web of Science ®Google Scholar
• Sampson SL, Dascher CC, Sambandamurthy VK et al. Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infect. Immun.72(5), 3031–3037 (2004).
   PubMed Web of Science ®Google Scholar
• Martin C, Williams A, Hernandez-Pando R et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine24(17), 3408–3419 (2006).
   PubMed Web of Science ®Google Scholar
• Williams A, Hatch GJ, Clark SO et al. Evaluation of vaccines in the EU TB Vaccine cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb.)85(1–2), 29–38 (2005).
   PubMed Web of Science ®Google Scholar
• Aguilar D, Infante E, Martin C, Gormley E, Gicquel B, Hernandez Pando R. Immunological responses and protective immunity against tuberculosis conferred by vaccination of BALB/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain. Clin. Exp. Immunol.147(2), 330–338 (2007).
   PubMed Web of Science ®Google Scholar
• Grode L, Seiler P, Baumann S et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette–Guerin mutants that secrete listeriolysin. J. Clin. Invest.115(9), 2472–2479 (2005).
   PubMed Web of Science ®Google Scholar
• Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun.71(4), 1672–1679 (2003).
   PubMed Web of Science ®Google Scholar
• Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat. Rev. Microbiol.4(6), 469–476 (2006).
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhu B, Wang Q et al. Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-γ confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice. FEMS Immunol. Med. Microbiol.51(3), 480–487 (2007).
   PubMedGoogle Scholar
• Tang C, Yamada H, Shibata K et al. Efficacy of recombinant bacille Calmette–Guerin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis. J. Infect. Dis.197(9), 1263–1274 (2008).
   PubMed Web of Science ®Google Scholar
• Wang JL, Qie YQ, Zhu BD et al. Evaluation of a recombinant BCG expressing antigen Ag85B and PPE protein Rv3425 from DNA segment RD11 of Mycobacterium tuberculosis in C57BL/6 mice. Med. Microbiol. Immunol. (2008).
   Google Scholar
• Edwards KM, Cynamon MH, Voladri RK et al. Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med.164(12), 2213–2219 (2001).
   PubMed Web of Science ®Google Scholar
• Sheridan JP, Marsters SA, Pitti RM et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science277(5327), 818–821 (1997).
   PubMed Web of Science ®Google Scholar
• Chattergoon MA, Kim JJ, Yang JS et al. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis. Nat. Biotechnol.18(9), 974–979 (2000).
   PubMed Web of Science ®Google Scholar
• Ziv E, Daley CL, Blower S. Potential public health impact of new tuberculosis vaccines. Emerg. Infect. Dis.10(9), 1529–1535 (2004).
   PubMed Web of Science ®Google Scholar
• Rubakova E, Petrovskaya S, Pichugin A et al. Specificity and efficacy of dendritic cell-based vaccination against tuberculosis with complex mycobacterial antigens in a mouse model. Tuberculosis (Edinb.)87(2), 134–144 (2007).
   Google Scholar
• Lore K, Adams WC, Havenga MJ et al. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J. Immunol.179(3), 1721–1729 (2007).
   PubMed Web of Science ®Google Scholar
• Bhatnagar S, Shinagawa K, Castellino FJ, Schorey JS. Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. Blood110(9), 3234–3244 (2007).
   PubMed Web of Science ®Google Scholar
• Giri PK, Schorey JS. Exosomes derived from M. Bovis BCG infected macrophages activate antigen-specific CD4+ and CD8+ T cells in vitro and in vivo. PLoS ONE3(6), E2461 (2008).
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y, Nakajima T et al. Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB. Vaccine25(16), 2990–2993 (2007).
   PubMed Web of Science ®Google Scholar
• Sadoff J. Aeras adeno 35 vectored and nucleocapsid vectored TB vaccines. Presented at: Viral Vector Vaccines Conference. Hinxton, Cambridge, UK 28–30 September 2008.
   Google Scholar
• Waddell RD, Chintu C, Lein AD et al. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin. Infect. Dis.30(Suppl. 3), S309–S315 (2000).
   Google Scholar
• Cardona PJ, Amat I, Gordillo S et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine23(11), 1393–1398 (2005).
   PubMed Web of Science ®Google Scholar
• Guirado E, Gil O, Caceres N, Singh M, Vilaplana C, Cardona PJ. Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis. Clin. Vaccine Immunol.15(8), 1229–1237 (2008).
   PubMedGoogle Scholar
• Santosuosso M, Zhang X, McCormick S, Wang J, Hitt M, Xing Z. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J. Immunol.174(12), 7986–7994 (2005).
   PubMed Web of Science ®Google Scholar
• Santosuosso M, McCormick S, Roediger E et al. Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization. J. Immunol.178(4), 2387–2395 (2007).
   PubMed Web of Science ®Google Scholar
• Garcia-Contreras L, Wong YL, Muttil P et al. Immunization by a bacterial aerosol. Proc. Natl Acad. Sci. USA105(12), 4656–4660 (2008).
   PubMed Web of Science ®Google Scholar
• Freidag BL, Melton GB, Collins F et al. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect. Immun.68(5), 2948–2953 (2000).
   PubMed Web of Science ®Google Scholar
• Palendira U, Bean AG, Feng CG, Britton WJ. Lymphocyte recruitment and protective efficacy against pulmonary mycobacterial infection are independent of the route of prior Mycobacterium bovis BCG immunization. Infect. Immun.70(3), 1410–1416 (2002).
   PubMed Web of Science ®Google Scholar
• Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette–Guerin immunity. J. Immunol.177(9), 6353–6360 (2006).
   PubMed Web of Science ®Google Scholar
• D’Souza S, Rosseels V, Denis O et al. Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect. Immun.70(7), 3681–3688 (2002).
   PubMed Web of Science ®Google Scholar
• Xing Z, Santosuosso M, McCormick S et al. Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines. Curr. Gene Ther.5(5), 485–492 (2005).
   PubMed Web of Science ®Google Scholar
• Casimiro DR, Chen L, Fu TM et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol.77(11), 6305–6313 (2003).
   PubMed Web of Science ®Google Scholar
• Wang J, Thorson L, Stokes RW et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol.173(10), 6357–6365 (2004).
   PubMed Web of Science ®Google Scholar
• Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun.74(8), 4634–4643 (2006).
   PubMed Web of Science ®Google Scholar
• Forbes EK, Sander C, Ronan E et al. The presence of multifunctional, high-cytokine-producing Th1 cells in the lung, but not spleen, correlates with protection against Mycobacterium tuberculosis aerosol challenge in mice. J. Immunol.181(7), 4955–4964 (2008).
   PubMed Web of Science ®Google Scholar
• Vordermeier HM, Huygen K, Singh M, Hewinson RG, Xing Z. Immune responses induced in cattle by vaccination with a recombinant adenovirus expressing mycobacterial antigen 85A and Mycobacterium bovis BCG. Infect. Immun.74(2), 1416–1418 (2006).
   PubMed Web of Science ®Google Scholar
• Kohama H, Umemura M, Okamoto Y et al. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette–Guerin (BCG) in infected mice. Vaccine26(7), 924–932 (2008).
   Google Scholar
• Fourie PB, Germishuizen WA, Wong YL, Edwards DA. Spray drying TB vaccines for pulmonary administration. Expert Opin. Biol. Ther.8(7), 857–863 (2008).
   PubMed Web of Science ®Google Scholar
• Hanekom WA. The immune response to BCG vaccination of newborns. Ann. NY Acad. Sci.1062, 69–78 (2005).
   PubMed Web of Science ®Google Scholar
• Worku S, Hoft DF. Differential effects of control and antigen-specific T cells on intracellular mycobacterial growth. Infect. Immun.71(4), 1763–1773 (2003).
   Google Scholar
• Cheng SH, Walker KB, Lowrie DB et al. Monocyte antimycobacterial activity before and after Mycobacterium bovis BCG vaccination in Chingleput, India, and London, United Kingdom. Infect. Immun.61(10), 4501–4503 (1993).
   Google Scholar
• Cheon SH, Kampmann B, Hise AG et al. Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis. Clin. Diagn. Lab. Immunol.9(4), 901–907 (2002).
   PubMedGoogle Scholar
• Wallis RS, Palaci M, Vinhas S et al. A whole blood bactericidal assay for tuberculosis. J. Infect. Dis.183(8), 1300–1303 (2001).
   PubMed Web of Science ®Google Scholar